Corporate Platform

Cooley handles 1,700+ private financings every year, earning its fourth consecutive PitchBook #1 ranking for representing venture-backed companies in venture capital financings. With an equal split of investor and company clients, we understand both sides of the table and the landscape of current market terms. Beyond just mechanics, we thrive on seeing deals happen. Our team recently advised ProfoundBio on its $112 million Series B financing, Red Tree Venture Capital on its co-lead investment in Bicara Therapeutics’ $108 million Series B financing and Zepto on its $200 million Series E financing.

Our exceptional public companies and securities law practitioners advise more than 250 public companies, their boards and board committees on all aspects of securities reporting and compliance and corporate governance. We advise public companies at all stages, from the newly public to large global brands, listed on US and non-US stock exchanges, in a variety of securities and corporate matters.

As Law360’s 2023 Capital Markets Group of the Year, Cooley represents companies, investment banks and investors in equity and debt transactions that raise capital through the global public and private capital markets. Cooley is the #1 firm for US public offerings – handling 1,000+ since 2016. Our recent transactions include advising Rubrik on its $752 million upsized initial public offering (IPO), Instacart on its $660 million IPO, Acelyrin on its $621 million upsized IPO and the underwriters in CG Oncology’s $437 million IPO.

Cooley is recognized across league tables as a top legal adviser for global M&A transaction activity – and as the only firm with equal gender representation in leading roles across public M&A transactions. Since 2019, Cooley has handled 1,500+ M&A transactions, with an aggregate value of more than $745 billion. We handle all types of transactions, including domestic and cross-border mergers and acquisitions, strategic deals, takeover defense and shareholder activism counseling, and multibillion-dollar public company mergers. Our recent transactions include advising Carmot Therapeutics on its sale to Roche for up to $3.1 billion, Everbridge on its sale to Thoma Bravo for $1.8 billion, Jackpocket on its sale to DraftKings for $750 million and Sazerac on its acquisition of BuzzBallz.

Cooley has represented clients on sophisticated private equity transactions since the earliest days of the private fund industry. We represent sponsors and their portfolio companies in connection with their acquisitions, divestitures and general corporate matters, with a particular focus on the middle market. Our recent transactions include advising Battery Ventures on its acquisition of GrammaTech’s software products, ChrysCapital on its acquisition of a 75% stake in ProHance Analytics and Rubicon Technology Partners on its investment in Ascend Analytics.

For more than 60 years, we have been an active player in the industry, forming the first venture capital limited partnership in the western US. As primary fund counsel to more than 700 investment fund organizations, we advise on every type of fund formation – including venture capital, funds of funds, private equity, evergreen, growth equity, and other managers at all stages and sizes, from individual angel investors to billion-dollar institutional funds. Our team recently advised Andreessen Horowitz (a16z) on the closing of $7.2 billion in new funds and Institutional Venture Partners on the raise of its $1.6 billion 18th fund

We have a top national debt finance practice, delivering results for public and private companies across industries. We assist issuers, underwriters/initial purchasers, institutional investors, private equity sponsors and their portfolio companies, and placement agents in navigating the full spectrum of debt financing and debt securities transactions. Our recent transactions include advising the underwriters on The Clorox Company’s registered debt offering of $1.1 billion and Snap on its $750 million convertible senior notes offering.